Dear Editor, Myelodysplastic syndromes (MDS) are hematopoietic disorders characterized by clonal hematopoiesis, recurrent genetic abnormalities, myelodysplasia, and a risk of progression to acute myeloid leukemia (AML) [1,2,3]. Despite the availability of various therapeutic interventions such as chemotherapy and hypomethylating agents (HMAs) to delay disease progression, allogeneic hematopoietic stem cell transplantation (HSCT) remains the only curative therapy [1].
Ko Sasaki
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Get in touch with Ko
Contact Ko, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack